Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Entadfi, a mix of finasteride and tadalafil, is used for BPH.

In this study, Deplanque et al. (2016) explored doxycycline's role in preventing erlotinib-induced folliculitis in patients with non-small-cell lung cancer, highlighting skin toxicity as a common side effect that can affect patient adherence to treatment.

Ethinylestradiol/Chlormadinone Acetate is a safe and effective birth control pill that also helps regulate menstrual cycles, reduces period pain, and treats certain skin and hair conditions.

This study evaluated the efficacy and safety of tofacitinib for treating severe alopecia areata in five patients, finding that three responded favorably with mild side effects, supporting its potential use based on existing research.

This review discusses the potential benefits of nonantibiotic macrolides for treating inflammatory skin disorders and reports no new clinical results.

In this study, brepocitinib was found to significantly reduce inflammatory biomarker CCL5 expression and improve clinical severity by week 24, while maintaining a favorable safety profile.

This study developed a new suspended ointment formulation containing neomycin sulfate and triamcinolone acetonide, which showed promise for treating neurodermatitis and chronic eczema by ensuring stable composition, effective skin penetration, and no skin irritation.

This case report suggests that clomiphene citrate can effectively restore fertility in some men with a long history of anabolic steroid abuse, though individual responses to treatment vary.

This study found that tofacitinib led to ≥50% hair regrowth in eight out of twelve patients with moderate to severe alopecia areata, suggesting a potential benefit for using JAK inhibitors in treating this condition.

This study found that the combined oral contraceptive containing ethinyl estradiol and chlormadinone acetate was effective in reducing moderate papulopustular acne and other androgen-related skin disorders compared to placebo.

Two women had skin reactions from a hair loss treatment and got better after stopping use.

This study found no significant difference in the effectiveness of betamethasone dipropionate cream compared to placebo for treating alopecia areata in children, and atopic status did not influence treatment response.

This article discusses the mechanisms and therapeutic use of antiandrogens, specifically cyproterone acetate and chlormadinone acetate, in gynecological treatments without reporting new clinical results.

This study reported that ZSYY001, a nanoparticle formulation of polymeric micellar paclitaxel, showed promising antitumor activity and was safe and well-tolerated in preclinical models and a phase I trial, without acute hypersensitivity reactions at doses up to 390 mg/m².

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

In this prospective study, 15 patients with patchy alopecia areata treated with intralesional methotrexate every two weeks showed a significant improvement in hair regrowth and reduction in lesion severity, with changes linked to decreased tissue levels of TNF-α.

This study discovered that TTR is expressed in the human placenta as early as 6 weeks gestation, with increased levels in the first trimester potentially facilitating thyroid hormone delivery to the fetus.

This review summarizes existing literature on the safety of commonly used dermatologic medications during pregnancy but does not present new clinical findings, aiming to assist physicians with prescribing decisions.

This study found that in treating mild to moderate acne vulgaris, topical tazarotene 0.1% was more effective than topical adapalene 0.1%, with 100% of patients using tazarotene achieving the desired outcome compared to 75.3% in the adapalene group.

In this study, researchers found that TCDD exposure accelerated differentiation and altered gene expression in human epidermal cells, indicating the epidermal barrier as a target of TCDD-activated AHR.

In this report, a 61-year-old woman with vitiligo showed significant improvement after tofacitinib treatment but developed lung adenocarcinoma, highlighting potential cancer risks associated with JAK inhibitors.

This study demonstrated the high effectiveness and safety of tofacitinib, a pan-JAK inhibitor, in treating severe forms of alopecia areata, although it is not yet FDA-approved for this condition.

This study found that combining Elidel with tretinoin was more effective for treating alopecia areata than using Elidel alone.

In this case report, a 14-year-old male with alopecia areata subtotalis and nail involvement showed significant improvement after 9 months of treatment with oral tofacitinib, including complete hair regrowth and nail texture improvement, though further studies are needed to confirm these findings.

This study reports that tofacitinib, a JAK inhibitor, may stabilize hair loss in patients with classic lichen planopilaris and frontal fibrosing alopecia, though hair regrowth was not robust.

This study found that econazole nitrate delivered via MPEG-dihexPLA micelles significantly increased skin deposition compared to Pevaryl® cream, potentially enhancing drug bioavailability and clinical efficacy.

This report describes a case where a young woman developed Kerion Celsi, a fungal skin infection, potentially linked to the use of a tretinoin, minoxidil, and betamethasone valerate lotion.

This review examines various immunomodulatory therapies for cutaneous lymphoma and notes that they are most effective in the disease's early stages.

In this study, tofacitinib and baricitinib showed similar effectiveness and safety in treating alopecia areata, but baricitinib had a higher rate of early responders. Baseline hair loss severity was identified as the only independent predictor of treatment response.

This study found that BD 1/4 dilution was the most effective corticosteroid concentration for intralesional injection to treat localized alopecia areata in adults, with fewer adverse effects than TA.